Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

By J. Byrd, R. Furman, S. Coutre, J. Burger, K. Blum, M. Coleman, W. Wierda, Jeffrey A Jones, Weiqiang Zhao, N. Heerema and 6 more. Blood, 2015

672 citations recorded by the source corpus.